Notifications about medicines to healthcare professionals
-
EMA’s Human Medicines Committee Recommends Wegovy in Tablet Form
| 22 May 2026 |
EMA’s human medicines committee (CHMP), part of the European Medicines Agency, decided at its meeting this week to recommend approval of Wegovy in tablet form. It is now for the European Commission to make the final decision.
-
PRAC assesses that NAION could be a very rare side effect of Ozempic, Rybelsus and Wegovy
| 19 March 2026 |
EMA’s Pharmacovigilance Risk Assessment Committee (PRAC) recommends that the product information for semaglutide medicines should include information that the rare eye condition NAION could be a very rare side effect. Treatment should be stopped if symptoms of NAION occur.